CLINICAL TRIAL OF THROMBOLYSIS IN MYOCARDIAL INFARCTION

心肌梗塞溶栓的临床试验

• 批准号: 3660151
• 负责人: ROBERT ROBERTS
• 金额: $ 49.79万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-07-15 至 1988-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3660151
• 关键词: cardiotonic agents; cooperative study; coronary vasodilator; drug administration routes; drug adverse effect; fibrinolytic agents; fibrinolytic therapy; heart disorder diagnosis; heart imaging /visualization /scanning; heart motion; human subject; human therapy evaluation; intracardiac volume; myocardial infarction; nitroglycerin; radionuclide diagnosis

Assess the efficacy of a thrombolytic agent in reducing infarct size and thereby improving ventricular function and subsequent morbidity and mortality. The primary endpoint will be total mortality during the follow up period. Secondary endpoints include determination of the: effect of thrombolytic therapy on left ventricular ejection fraction;proportion of patients suspected of having myocardial infarction with complete versus incomplete occlusion of the infarct related artery; time limits for successful reperfusion including differences according to the route of administration; and frequency and severity of adverse effects of intracoronary and intravenous administration of thrombolytic agents in patients with acute infarction.

评估溶栓剂在减少梗塞大小和 从而改善心室功能和随后的发病率和 死亡。 主要终点将是以下过程中的总死亡率 上升期。 次要终点包括确定： 左心室射血分数上的溶栓疗法；比例 涉嫌完全与完全相对于心肌梗死的患者 梗死相关动脉的不完全阻塞；时间限制 成功再灌注，包括根据途径的差异 行政;以及不良影响的频率和严重程度 冠状动脉内和静脉内溶栓剂 急性梗死的患者。